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Abstract

Relationships among demographic, socioeconomic and person factors and Opioid Use
Disorder diagnosis, treatment, and recidivism were explored. Data from a sample of
4,860 adults with substance use difficulties were analyzed. A program evaluation was
conducted on Gateway Community Services to explore the use of Medication Assisted
Treatments (MATs) and Psychosocial (PS) treatments to address Opioid Use Disorder.
Using archival data, a chi-square analysis and independent sample t-test was performed.
The results expressed that a relationship among race, type of substance use diagnosis, and
treatment type and recidivism rate was found. While White/Non-Hispanics adults were
more likely to use heroin than any other racial/ethnic backgrounds, gender differences
were also found. Finally, frequency and duration of a combined treatment (PS + MAT)
were negatively related to recidivism with no determination of previous prescription
opioid use to be examined at this time.
Keywords: medication assisted treatment, recidivism, psychosocial, opioid, heroin
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Opioid Use Disorder: The Ugly Return and Treatment Effectiveness of Heroin Use
The topic of substance use negatively touches, affects or presents itself to nearly
every family, school, workplace or community. Those who struggle with substance use
unduly impact those near them in ways that exceed the mere duration of intoxication. For
example, there are financial costs (e.g., court, DUI, medical), lost potential, and direct
theft of family members that add up over time. Beyond the immediate family, patterns of
substance use in a community ebb and flow across time. One pattern of substance use that
has a particularly unique and problematic history in the United States and even more
sharply in Southeast Georgia/Northeast Florida is that of Opioid use. The current study
will review the history of opioid use within the United States and in the immediate
Southeast Georgia/Northeast Florida region. Further, this investigation will explore the
relationships among demographic, socioeconomic, person factors, and opioid use, and
will evaluate the relation of various treatment options with recidivism.
Literature Review
Substance use problems have been noted in the literature throughout the ages
(e.g., the army of Alexander the Great and its reliance on alcohol for engagement and
continued conquest; Sir Arthur Conan Doyle penning Sherlock Holmes in opium dens).
Beyond romantic depictions of use, the struggles related to substance use have not
diminished in importance or acuity or in their more accurate reality of costly and tragic
impact and outcomes. In recent decades, individuals like Marilyn Monroe and Robin
Williams committed surprising suicides, with their life stories revealing significant
struggles with mental health issues and illicit and prescribed substance use (Bloomquist,
2008).
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Diagnostic Considerations
The diagnostic process and conceptualizations of substance use have changed
over time. Early research and literature on substance use coined and used the terms
addictions and drugs. Addiction was acknowledged as a process whereby a behavior, that
functions to produce pleasure and/or escape from internal discomfort, is employed in a
pattern characterized by (1) recurrent failure to control the behavior and (2) continuation
of the behavior despite significant negative consequences (e.g., getting fired from a job,
losing a relationship; Goodman, 1990). Goodman also defines a drug as a construct
representing any substance that when it enters the body, it alters the body’s functioning in
a physical or psychological manner; with the exceptions of food and water, and of legal
or illegal status. In contrast, the more expansive concept of a substance has been defined
in research as a physical material of discrete existence or particular matter of definite
chemical constitution deemed harmful and usually subject to legal restriction.
In the American Psychiatric Associations Diagnostic and Statistical Manual of
Mental Disorders - Fourth Edition (American Psychiatric Association (APA), 1994),
substance use struggles were diagnosed as either Substance Abuse or Substance
Dependence. Substance Abuse was described as involving problematic but acute
struggles with substance use, such as going on repeated weekend benders, with continued
functionality, and no tolerance issues. Substance abuse was understood as the
overindulgence in an addictive substance, marked by a change in behavior caused by the
biochemical changes in the brain after continued substance abuse.
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Substance Dependence was defined as having chronic struggles with a pattern of
substance use, prior failed attempts at quitting usage, and tolerance and withdrawal
effects Substance dependence was categorized by the compulsive and repetitive use that
may result in developing a tolerance to the effects of the drug and symptoms of
withdrawal if the use is reduced or stopped In the current Diagnostic and Statistical
Manual of Mental Disorders – Fifth Edition (DSM-V)(APA, 2013), substance use issues
have been collapsed into Substance Use Disorder diagnoses by category of substance.
Illicit opioids, prescribed analgesic misuse and heroin use are all diagnosed as Opioid
Use Disorder, with a specifier of mild, moderate or severe noting the level of struggle
(APA, 2013). Therefore, Substance Use Disorder replaces terms such as drug abuse,
substance abuse and dependence. Substance Use Disorder is thus defined as the recurrent
use of alcohol and/or substances causing clinically and functionally significant
impairment. Substance Use Disorder is also represented as a behavior pattern
characterized by overwhelming involvement with the substance and its use despite the
adverse penalties it creates (Straub, 2014). The American Psychiatric Association and
substance use researchers have further enhanced the elements, dimensional
characteristics, criteria or requirements, and categorical organization for substances used
in a problematic manner within the Diagnostic and Statistical Manual of Mental
Disorders – Fifth Edition (DSM-V). The DSM-V allows for diagnosis of Substance Use
Disorder via the use of sets of criteria that establishes criteria for eight different
categories of substance-related disorders and the diagnostic severity level (Horvath,
Misra, Epner, & Cooper, 2016).
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Opioid use disorder. Of those eight categories, Opioid Use Disorder has striking
local relevance to the population of Northeast Florida due to its historical pattern of usage
– drifting from one opioid substance to another, both across the population and within
individual case histories - and its impact on both users and the medical field. In the midto late-1800’s, opium was a popular substance. Initially thought to be harmless and
useful, it was used as a common pain medication within medical operations or traumatic
injuries, as well as for less invasive, common issues like coughs or sleeplessness (Booth,
2013). Because of its aid in such arenas, it continued to be heavily marketed as being
non-addictive. However, as time passed, there was an awareness of the possibilities of
misuse and a shift in the understanding of just how powerful heroin and other opioids
could actually be.
Prevalence and Relevance
Comparing the misuse of medications by category in 2015, 12.5 million people
misused opioid pain medications (4.7 %), 6.1 million misused tranquilizers (2.3 %), 5.3
million misused stimulants (2.0 %), and 1.5 million misused sedatives (0.6 %; Hughes et
al., 2016). The numbers suggest that our societal struggles with opioids far outweigh
those of other misused medications. It is estimated that between 26.4 to 36 million
people abuse opioids worldwide and 2 million people in the U.S. suffer from substance
use disorders related to prescription opioid pain relievers as of 2012 (NIDA, 2014).
When looking at the prevalence of opioid misuse and its relevance, it is important
to discuss the demographics of those persons. An individual plagued with a substance use
disorder does not represent a specific demographic. This disorder reaches that of all
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races, ethnicities, sex, and socioeconomic status. All demographics represent a
fluctuation of use between years 1975 to 2015. For instance, according to the Centers for
Disease Control (CDC), “The age-adjusted drug poisoning death rate involving opioid
analgesics increased from 1.4 to 5.4 deaths per 100,000 populations between 1999 and
2010, decreased to 5.1 in 2012 and 2013, then increased to 5.9 in 2014, and to 7.0 in
2015. The age-adjusted drug poisoning death rate involving heroin doubled from 0.7 to
1.4 deaths per 100,000 resident populations between 1999 and 2011 and then continued
to increase to 4.1 in 2015.” (CDC, 2015). This information showed an ultimate increase
of death rates for all ages, all sexes, all races, and all ethnicities for opioid and heroin
related deaths by year 2015 from year 1999.
Demographics of Users
To further address demographic information, we must establish a general
consensus on addiction. Addiction is shown to not be a moral failing or a character
defect, but an ongoing yet fixable brain disease categorized by compulsive substance
abuse and repeated relapse (APA, 2017). This idea of addiction is important to
acknowledge as it expresses the history of treatment for addiction as well as the history of
use. There was evidence that an addiction took place, and then the individuals were
isolated. After, the heroin addiction shifted to individuals that were of minority decent
and below the poverty line. The trend continues to shift because in more recent history,
the make-up of those individuals using heroin in the 1960s were predominantly men
(82.8%, mean age 16.5 years) and their first experience with opioid use was heroin
(Booth, 2013). However, In recent studies, users are older (M = 22.9 years old) men and
women living in less urban areas who were introduced to opioids through prescription

OPIOID USE DISORDER: THE UGLY RETURN AND TREATMENT

6

drugs (75%), with 90% of which that began using in the last decade being white (Cicero,
Ellis, Surratt & Kurtz, 2014). Specific to prescription drugs representing a gateway, the
CDC reported that the misuses of prescription opioid medications killed 18,893 people in
the U.S. in 2014 with an additional 10,574 individuals dying from heroin overdose (CDC,
2015). As well, in 2011, the rate of overdose deaths from opioid prescription drugs was
highest in states with higher poverty levels. Currently, the epidemic that has been
discussed in the literature acknowledges that young White Americans in rural areas of
practically every state are using heroin (Bowser, Fullilove, & Word, 2017). Additionally,
there is a shift in the way drugs are sold due to phones, messaging, and the internet. As
well, heroin sellers are distributing to suburban and exurban areas, which means there is
no longer need for distributing to urban black and Latino minority communities to sustain
profit.
Medical versus Non-Medical Use
When medication is used as intended after it is prescribed, it can be a useful tool
that benefits the medical patient by helping to reduce pain, enhance, sleep, reduce painrelated irritability, and improve social and work functioning. Medications like Opioids
can help patients who struggle with chronic pain issues to find enough relief to allow for
productive work and healthy lifestyles. A current consideration for Opioid Use Disorder
is whether the opioid use is for medical or non-medical purposes (Boyd, Cranford, &
McCabe, 2016). Such a medical versus non-medical consideration includes “shades of
gray,” as an individual’s use of an opioid pain medication may once have been a
legitimate effort to address injury-related or post-surgical pain but may evolve over time
into non-medical use. This takes place if the opioid use extends past the duration of time
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required for most patients following similar procedures or injuries. Recent data from
Boyd, Cranford, and McCabe (2016) also suggests that people in the United States use
approximately 80% of the world opioid supply despite making up only 5% of the world’s
population. Unfortunately, a good portion of that 80% of opioid supply usage is likely not
legitimate.
Types of Opioids
There are many types of opioids that are used and possibly abused. For instance,
the pharmaceutical opioids are those such as codeine, morphine, hydrocodone,
oxycodone, methadone, buprenorphine, and fentanyl and could represent a high level of
injection (Ambekar, Rao, Mishra, & Agrawal, 2015). Heroin is an opioid drug made
from morphine which can be of a white or brown powder, or a black sticky substance
(NIHA, 2016). Heroin produces similar responses as morphine and codeine but is cheaper
to produce and get on the street. For instance, the average cost of a single dose of heroin
is approximately $15-$20 depending on purity and availability with a dependence costing
an individual $150-$200 a day (Perdue, Sherba, Gersper, & Martt, 2015). An individual
injecting heroin may spend more. However, without insurance, an individual with chronic
pain would possibly spend over a thousand dollars a month for a prescription opioid out
of pocket if they are limited. However, the economic burden of illicit opioid use in 2013
was estimated to be about 78.5 million dollars for health care, criminal justice costs, and
substance abuse treatment (Florence, Luo, Xu & Zhou, 2016).
Biological process and opioids. Opioids such as morphine and heroin mimic
endorphins (the body’s natural opiates), and molecules of the synthetic opiates bind to the
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receptor sites for endorphins, stopping the body from naturally producing opiates (Straub,
2014). Opiate drugs exert their effects by binding to three opioid receptor types mu, delta,
and kappa receptors. These receptors mimic the actions of endogenous opioid peptides:
the endorphins, encephalins, and dynorphins. An endorphin, encephalin, and dynorphin
are analgesics and properties of opioid receptors responsible for euphoria, tolerance,
dependence and sedation (Tordjman et. al, 2003)). They are also responsible for immune
suppression and stimulation as well as respiratory depression and myosis. These
receptors, through second messengers, influence the likelihood that ion channels will
open, which in certain cases reduces the excitability of neurons. Through neuroimaging
displaying the involvement of the frontal cortex, we learned that opioids bind to these
opiate-specific receptors which activate the reward system and increase levels of
dopamine (Goldstein & Volkow, 2002). Added research has expressed that opiate
alkaloids are known to suppress immune function by acting on the brain and producing
effects such as euphoria by activating both the hypothalamic-pituitary-adrenal axis and
the sympathetic nervous system (Wooten & Guthrie, 2012). Additionally, studies have
found that there are various systems involved with opioid use related to heroin.
Specifically, Heroin is represented as a full opioid agonist and activates all opioid
receptors completely (De Vries & Shippenberg, 2002). Heroin’s relationship to opiates
presents a relationship that warrants further analysis of the process of heroin dependence
before treatment can efficiently take place.
Transitions within opioid use disorder. An interesting pattern observed by law
enforcement is that a good portion of individuals appear to transition among types of
opioids over time. As a stand-alone issue, heroin has been a long-standing illicit
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substance sought after by individuals who seek its intoxication effects. However, a
portion of users are thought to have initially used prescription opioid medications prior to
using heroin, also evidenced by research studies. Concern has risen about individual
usage involving a transition from opioid medication misuse to heroin usage. Initial
legitimate use of opioid pain medication following surgery or injury may become illicit
or inappropriate use of the patient continues to seek opioids after their medical need
ceases (e.g., pain subsides, healing occurs; Mars, Burgois, Karandinos, Montero, &
Ciccarone, 2014). It is important to revisit the difference between medical versus illicit
forms of opioids because during the past decade, while pharmaceutical medications have
risen in cost, the price of street heroin has dropped (Unick, Rosenblum Mars, &
Ciccarone, 2014). What experts fear is that due to the relatively lower cost of street
heroin versus prescription opioids, individuals may be seduced to the use of the less
costly heroin alternative (Cicero, Ellis, Surratt, & Kurtz, 2014). In turn, seeking pure
heroin for pain has itself undergone change, with a rise in fatalities from use of heroin
revealing a “laced” nature of the heroin. Fentanyl and other substances appear to be
making heroin injections yet more lethal (Stogner, 2014). With the ideas of cracking
down on the opioid prescriptions, the higher costo of out of pocket purchase becomes
more of an opportunity to buy these substances on the streets. However, it is important to
note how rapidly the addiction transitions.
Overprescribing of opioid pain relievers has led to a major increase in the status
of opioid addiction, which has been associated with a rise in overdose deaths and heroin
use (Kolodny et al., 2015). Because heroin mimics the reaction of prescription
medication, it is said that nearly 80 percent of Americans using Heroin reported misusing
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prescription opioids prior to heroin. The increase of heroin use is not the only clear
change in the realm of substance use. There appears to be a shift in the demographics of
those individuals using heroin. Within this shift in demographics, there is an increase in
use in suburban areas. Such a transition must be explored because pathways to heroin use
may differ in suburbia than those followed in more impoverished or urban populations
within the United States. How does a person with adequate resources and housing begin
to use heroin? Are there gateway medications or substances that make heroin usage more
likely? Also, what treatments of Opioid Use Disorder are related to more positive
outcomes?
Treatment
In history, addiction was treated as a moral flaw. In this, treatment consisted of
imprisonment and admittance to insane asylums (Torrey, Stieber, & Ezekiel, 1998). Over
the decades a shift took place to now view addiction as a brain disease characterized by
fundamental and long-lasting changes in the brain. Treatment consists of detoxification
which is a method of going through withdrawal brought on by isolation of the individual
to focus on the physical symptoms of withdrawal. Detox was recognized in the past as a
necessary part of rehabilitation but it was a painful process alone. Cognitive and
Behavioral Therapy (CBT) was then implemented such as counseling, support groups,
and other forms of therapy to address the emotional aspect of substance abuse and assist
with preventing relapse (McHugh, Hearon, & Otto, 2010).
Today, there are controversial drugs used to assist in the recovery process called
Medication Assistance Treatment (MAT) (Center for Substance Abuse Treatment, 2005).
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These forms of treatment are used in combination with detoxification and CBT. MAT is
medication used to assist with treating cravings and preventing relapse which buys time
for the CBT to work efficiently and assists with the painfulness of detoxification.
There are several forms of drugs that are usually used in MAT. The drugs
specific to opiate use and abuse are naloxone, methadone, and buprenorphine to name the
popular forms. Naloxone is a drug that blocks or reverses the effects of opioid
medication. Drugs like methadone and buprenorphine are used to reduce withdrawal
symptoms and relieve pain (Griffin et. al, 2014). A combination of buprenorphine and
naloxone creates a drug called Suboxone that has recently become popular. Suboxone is
used for treatment and opioid dependence and should be used as a part of a complete
treatment plan including counseling and support.
With our changing attitude of what substance use disorder is classified as, comes
our changing need to provide effective treatments for Opioid Use Disorder. Treatment is
now to be provided through Medication Assistance Treatment (MAT) as well as
Cognitive Behavioral Therapy (CBT) coupled with traditional forms of treatment. Most
importantly, the decision to use Suboxone as a form of MAT marks a new wave of
understanding the disorder that is taking so many lives. The idea is then to address
demographical shifts, changes in identification, and change in treatment to provide the
best and most responsive form of care for the individuals plagued with this disorder.
Treatment Success
In 1962, researchers attempted to use morphine as a medication maintenance
for substance use disorder and realized that morphine may not have been a good choice
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due to its’ similar characteristics of heroin, oxycodone, and codeine (NIDA, 2016).
Methadone maintenance was introduced as a possible treatment for substance abuse and
in 1965, an expansion took place to measure the chances that methadone would not
provide too many euphoric side effects to the patients. In 1985, researchers learned that
methadone assisted withdrawal would need to consist of gradual methadone reduction
versus other forms such as using clonidine because it resulted in higher withdrawal
symptoms and discomfort (Rounsaville, Kosten, & Kleber, 1985). Researchers also
opined that inpatient opioid detoxification would be a useful strategy for patients with
severe psychological symptoms (San, Cami, Peri, Mata, & Porta, 1989). Methadone
treatment recently has also expressed differences in sex. In a study conducted in 2015,
there was evidence of a sex difference in polysubstance use, legal involvement, and
employment status for men and women receiving methadone treatment (Bawor et al.,
2015). As well, there has not been a particular weaning strategy identified to be universal
for the individuals taking methadone over other prescribed infusion weaning for opioid
addiction (Dervan, Yaghmai, Watson, & Wolf, 2017). Methadone has a proven success
rate in handling opioid addiction; however, there is a higher probability that methadone
users will not be able to get off of the methadone without replacing this medication with
another one.
For the possibility of finding a medication combination that could assist with
weaning as well as complete sobriety, researchers continued to explore other options. In
specific, Suboxone has been found to be a less addictive medication treatment that can be
prescribed at home. Further, its withdrawal symptoms are less severe than are those from
alternative medications (Volkow, 2014). While Methadone is currently cheaper and has
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been found to provide better relief in some studies, Suboxone has provided hope in
regards to individuals needing substance use treatment but who are unable to get into or
stay within residential treatment programs. In a study conducted on two-year treatment
rounds with Suboxone, 75 percent had a successful response to the use of Suboxone with
43 percent remaining in Suboxone treatment, 21 percent tapering off successfully, and 58
percent reporting receiving CBT (Finch, Kamien, & Amass, 2007).
For the individual, Suboxone has been shown to decrease cravings and relieve
withdrawal symptoms. Suboxone has been available since 2003. An estimated 400,000
people in the world are using it for opioid dependence (Fuller & Moore, 2017). There is
not much information available about who exactly it assists or how it assists that person
other than the generalized form of assistance with cravings and withdrawal. In relation to
the universal aspect of Suboxone, it is recommended that suboxone be taken in
conjunction with CBT and a full comprehensive treatment plan. Studies have shown that
combining Mat with psychosocial support strategies such as CBT and support groups
represent the best way to treat opioid addiction effectively (Lobmaier, Gossop, Waal, &
Bramness, 2010). It is important to note in that Suboxone is underrepresented in regards
to population it serves as well as the many trials that have been done. Although
Buprenorphine is represented as a form, the connection with naloxone and its’ success
rate in addressing dependence is understated therefore, further research should be
conducted.
Hypotheses
Three main hypotheses were tested in the current investigation:
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1) White/Non-Hispanic adults were expected to be more likely to meet diagnostic
criteria for Opioid Use Disorder and use MAT treatment options more than were
individuals from other racial/ethnic groups.
2) White/Non-Hispanic adults were expected to be more likely to have a history of
Opioid medication misuse (versus other substance usage) prior to using Heroin,
compared to users from other Race/Ethnicity backgrounds.
3) Combined Psychosocial (PS) and Medication-Assisted Treatment (MAT) services
were expected to be related to more positive outcomes or “success” than were
individual PS interventions.
Methods
Via an application and initial review by the University of North Florida
Institutional Review Board (Project # 1154144-1), the IRB informed the researchers of
the project’s exempt status, with permission granted for use of archival data. The data
was provided by a data collection and storing system generated by Gateway Community
Services (GCS). GCS is a facility with an assortment of treatment and recovery based
forms of services such as detoxification, CBT, and MAT. This program also provides
individual and group counseling, support groups, and medications such as Suboxone.
This facility was used due to the many programs of treatment that the patient may
participate in and the knowledge and use of substance abuse diagnoses that are explored
throughout an individual’s inpatient and/or outpatient stay with GCS.
Variables. For the use of variables, demographic information age (no birthdate),
sex, race, ethnicity, marital status, parental status, education level, employment status,
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annual family income, and was explored for each of the individuals. This demographic
information was as follows: The reality of comorbid substance use (e.g., misusing more
than one substance at a time was addressed in the GCS database via the use of Primary
(substance of first choice for usage), Secondary (second choice) and Tertiary (third
choice) substance categories. Treatment Completion was identified for Psychosocial (PS)
and Medication-Assisted Treatment (MAT) interventions in a “Yes or No” manner.
Individuals identified as using heroin also were coded in a “Yes or No” manner. While
these variables were provided, the demographic variables that were of most important
were race, ethnicity, marital status, education level, employment status, length of
program enrollment, and reason for discharge. Recidivism was defined as the number of
times a participant returned for substance use treatment. Dose Effect was defined as the
number of treatments/sessions. Treatment Outcome was defined as the combination of
Treatment Completion and Recidivism.
Data Cleaning. Archival data was originally collected by GCS staff evaluators
who administered client assessments upon client application and entry to the treatment
facility. Additional GCS staff entered and coded the data into a main GCS database. The
individuals provided information for their top three substances of choice for use while
undergoing intake assessment as well as a urine analysis that evaluated the individuals’
substance use more concretely upon entering GCS treatment. At that time, authorization
via release forms, and multiple consent forms were collected from the individual for
treatment and collection of the information. The data used for the current study
represented 2014-2015 data from adults treated at the GCS facility.
Results
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The results of this student are presented in two parts. First, the sample
composition will be described. Second, findings addressing the three proposed
hypotheses (regarding the racial/ethnic background differences for Opioid Use Disorder,
the relationships among Opioid Medication Misuse, Heroin use, and Race/Ethnicity, and
the relations among treatment type and treatment outcomes) will be reported. All
analyses were conducted using SPSS 22.0.0.0.
Sample composition. Data from 4,860 adult treatment participations at GCS
during years 2014 and 2015 was included for analyses. The participants ranged in age
from 18 to 86 years in Age, with Duration of Recovery or Treatment ranging from 1 to
862 days. In addition to Heroin and Opioid Medication misuse, there was a long list of
substances misused by clients treated at GCS. Individuals with missing data for substance
type and treatment type were excluded from the Hypotheses tests.
Individuals treated at GCS were predominantly male (59%). The sample was 65%
White, 30% Black, and 5% identifying as American Indian/Alaskan, Asian, Hawaiian/
Pacific Islander, or Multi-Racial. In terms of marital status, 63% were Never Married.
Approximately 34% reported earning a high school diploma. A majority of the sample
self-identified as Unemployed (53%). (Please see Tables 1, 2, and 3 for Demographic
information).
The two main treatments provided for Opioid Use Disorder were Psychosocial
Treatments (PS; e.g., individual or group counseling, 12-step programs) and Medication
Assistance Treatment (MAT). While PS treatment is used at GCS to treat individuals
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with a wide variety of Substance Use Disorders (e.g., Alcohol, Cocaine, Heroin),
Suboxone-based MAT is used specifically for Opioid Use Disorder.
Less than one quarter (17%) of individuals treated at GCS during 2014-2015
received MAT treatment. MAT treatment appropriately targeted heroin and other opioid
use. A chi-square was run on primary, secondary, and tertiary substance use related to
heroin and MAT treatment. As the literature highlights the correlation between heroin use
and other opioid use (opioid medication misuse), it was important to explore the validity
of MAT treatment provision at GCS.
Hypotheses Tests
Race/Ethnicity differences in heroin use. To explore whether White/NonHispanic adults would be more likely to struggle with Opioid Use Disorder than would
persons from other racial/ethnic groups, a Chi-square analysis by Race/Ethnicity
(White/Non-Hispanic, White/Hispanic, Black/Non-Hispanic, Black/Hispanic,
Multiracial, Other) and on Heroin Use (Yes, No) was conducted. As predicted, group
differences for heroin use were observed, X2(7, N=4605) = 96.13, p < .001, with
White/Non-Hispanic adults more often using heroin, than any other race/ethnicity (see
Figure 13).
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Figure 13. Heroin use (yes or no) by racial and ethnic identification.
In follow-up post-hoc analyses for Race/Ethnicity, gender differences were
explored for White/Non-Hispanics, a Chi-square analysis by Gender (Male, Female) on
Heroin Use (Yes, No) was conducted. The relation between these variables was
significant, X2(1, N= 2902) = 7.81, p < .001, with Males more likely to use Heroin than
were Females (see Figure 14).
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Figure 14. Heroin use (yes or no) by gender (male or female).
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Opioid medication misuse and heroin use. Due to the limits of available
information in the archival data, timing of usage (e.g., misuse of Opioid medications
prior to (versus after) Heroin could not be determined. Instead, the researchers compared
frequencies of reported simultaneous use of other common substances to the use of
Heroin using a Chi-square analysis by Heroin and Other Substance (Alcohol,
Benzodiazepines, Cocaine/Crack, Methamphetamines, Cannabis/Marijuana, and Other
Opioids) for White/Non-Hispanics),with notably group differences in probability found
for Secondary Substance, X2(6, N=915) = 25.63, p < .001, but not for Tertiary Substance,
, X2(6, N=378) = 9.01, p < 0.17 (see Figure 15).
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Figure 15. Heroin use (yes or no) by identified secondary substance of choice.
Post-hoc analyses for Secondary Substance found that White/Non-Hispanics
were no more likely to use Other Opioids versus other secondary substances along with
Heroin use, ps > .10.
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Treatment Effectiveness. To evaluate the relations among treatment type and
client outcomes, the relationships among Combined Psychosocial and MedicationAssisted Treatment (PS+MAT) were compared to Psychosocial treatment alone (PS).
Treatment Success was measured as a combinative score of Treatment Completion,
Treatment Outcome (judgement by clinicians as free of substance use or not), and
Recidivism (number of returns to GCS for additional rounds of treatment), with lower
Treatment Success scores indicating greater success. An independent samples t-test was
run, with results finding that individuals treated with only PS had greater success (M =
2.29, SD = 1.5) than those treated with both PS and MAT (M = 3.45, SD = 3.1), t(194) =
3.53, p = .001 (See Figure 16, noting the inverse scoring for success; e.g., lower scores
indicate greater treatment success). Treatment type was associated with recidivism rates,
with combined psychosocial (PS) and medication Assisted Treatment (MAT) treatment
negatively related to recidivism, while individual PS only treatments were positively
related to recidivism, p < .05. Individuals that remained in treatment for an extended
length of time or throughout the entire duration of treatment were more likely to complete
treatment successfully in both combined and individual treatment methods, p < .05 (see
figure 16).
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Figure 16. Treatment success by PS versus MAT and PS combined.
Discussion
Demographics revisited. Suboxone or MAT seems to represent a practical
treatment opportunity for heroin and other opioid addiction (Sittambalam & Ferguson,
2014). It also seems to have impact on cocaine/crack users. There showed to be a
significant response of MAT use for individuals with a secondary diagnosis of heroin.
With regards to the hypotheses, White non/Hispanic individuals did prove to use heroin
and other opioids more than other racial/ethnic backgrounds. However, the data also
expressed that females were more likely than males to use other opioids and more likely
to participate in MAT treatment even though males made up more of the population. This
information may be related to barriers to treatment that may need to be explored for
males such as more thorough explanation of the treatment options, explanation of cost,
and benefit (Priester, Browne, Iachini, Clone, DeHart, & Seay, 2016). There also may be
a different form of reasoning for exploring these options such as being involved with
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child welfare services. As well, there were crucial findings in regards to those individuals
in the facility being of non-Hispanic descent, being of White racial identification, never
married (see Figure 5), and being somewhere between 9th to 12th grade or achieving a
high school diploma/degree (see Figure 6). There were also findings related to those
being unemployed making up a vast percentage of the population which suggests that
there is a continuous link between unemployment and substance use disorders (see Figure
4). There was also acknowledgement that White individuals made up more of the
population than any other race entering into the treatment facility. This represented a shift
in the individuals using drugs as a general evaluation. Interpretation for the demographic
findings are related to the literature in that there are increases in opioid use across all
categories of demographics (Rudd, 2016).
Other recent studies have acknowledged that the demographics of heroin and
other opioid users has been that of individuals identifying with White males of ages 2129 and 35-44 (SAMHSA, 2011). The range in this study provided that there was not a
significant age because of the spread of individuals entering into the facility. Again,
related to demographic information, the more information we used in our analyses, the
less of a difference we experienced. However, individuals identifying as white/nonHispanic and male had a high probability of using heroin and other opioids in this study.
They were also more likely to enter a substance use facility than individuals of other
demographic markers.
Duration and education of treatment. Additionally, with regards to recidivism,
the study did display that individuals that remained in treatment for a longer period of
time were more likely to complete the treatment episode successfully. The recidivism
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extends to individuals in MAT treatment as well. For the traditional PS treatment, there
seemed to be a duration effect related to treatment and successful completion. However,
in regards to Suboxone treatment as this facility, each individual that receives any form
of MAT has to be provided education about the programs available. They must also be
involved in some form of after-care program (groups or meetings), must initially go
through detoxification to be put onto the medication and monitored to verify dosage, and
must meet with the doctor to verify dosage on a scheduled basis beginning with meeting
weekly for dosing and then more weeks between doses.
Addressing the hypotheses. In regards to the hypothesis pertaining to previous
prescription and opioid use, relations between heroin use to prior prescribed opioid
treatment was explored but unable to be confirmed at this level of analysis with this data
set. However, educational attainment and polysubstance use at baseline were discovered.
Most of the individuals entering treatment identified with an alcohol related substance
use disorder which is related to limitations of this study. However, for those individuals
that identified with a heroin or other opioid use disorder, they majorly represented the
White/Non-Hispanic population. Frequency and duration of combined treatment with
psychosocial (PS) and medication (M) treatment was negatively related to recidivism,
while individual treatment with PS displayed slight positive correlations to recidivism.
Related to the literature, the desire of the current study was to find a link between
opioid use and prescription opioids. This hypothesis would have been beneficial in
exploring the gateway of use and how to address this matter in prescribing medications to
the individuals in the substance abuse facility. Studies have expressed that there is a
definite link but many are observational and don’t provide directionality (Compton,
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Jones, & Baldwin, 2016). This study sought to explore a directionality effect but due to
the way in which the variables were collected and the form of assessment, there was
limited information on prescription medication.
Furthermore, with the structure of an outpatient facility monitoring the dosage,
the education related to the medication, and the addition of psychosocial treatment
options, the MAT treatment could prove successful in treating related substance use
disorders. Additionally, other studies have shown that Suboxone is explored because it
allows for lower chance of dependence, and milder withdrawal symptoms (Schottenfeld,
Pakes, & Kosten, 1998; Mattick, Kimber Breen, & Davoli, 2004). While this direct
information was not covered in this study, Suboxone treatment does seem to prove a
worthy investment related to tackling the opioid use disorder. However, due to the timing
of introduction to the use of MAT in this facility, the stage of the epidemic at the time of
the data collection, and the lack of follow-up information provided for the individuals,
there does not show to be a significant benefit to use of MAT and PS in this facility at
this time. Further study should be explored related to more recent data at the facility and
compared to the use of MAT services at other facilities in the area.
Limitations. There was minimal information for how many times an individual’s
service count (meaning the amount of services an individual was receiving). Therefore,
when an individual did receive services, there was not much information related to what
order that individual received services but simply how many times. That may be
problematic in addressing the amount of times an individual relapsed. As well, there was
no direct indicator for follow up for a year or more after completion of the episode. This
means that there is no way to evaluate whether or not the individual checked into another
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treatment facility or died or relapsed and did not come back to the facility. This is the
same for individuals that leave the Suboxone program.
Additional limitations are related to the fact that the study was specific to one
treatment facility and cannot account for the statistics of others however; the attempt of
using such a large sample size was to be able to generalize to more demographics. As
well, by connecting with other treatment facilities to evaluate their use of data collected
and treatment forms would allow for more generalizability.
Also, it should be noted that there are certain criteria that must be met for
individuals to enter into the substance use facility. Those criteria are represented by a
certain combination of substances having to be in the system at the time of arrival to the
facility for possible admission. This means that the diagnoses of alcohol use disorder may
be a part of a technicality because it is a guaranteed substance allowing for admission
into detoxification. As well, this study represented a heavily correlational design.
In conclusion, the likelihood of treatment success was related to the length of
program stay. Suboxone as a treatment option for heroin and parallel substance use
disorders proved beneficial in regards to recidivism. With the correct amount of
education and outpatient guidance, an individual in the program may be more likely to
complete the program than individuals not pursuing MAT. However, without follow-up
data for the individuals, it is not possible to identify what path the individuals took after
completing the episode of care or if they are currently enrolled in treatment elsewhere.
In order to prevent relapse and sustain recidivism, further information should be
explored pertaining to the current use of suboxone in facilities and all of the limitations
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must be addressed. It is important to educate the staff as well as ensure that the
individuals receiving treatment continue to understand their rights and the benefits of
maintaining sobriety. By increasing awareness of the options for individuals with opioid
related substance use disorders, there could be a decrease in the number of lives claimed
by this opioid epidemic.
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Table 1
Means and Standard Deviation for Adult Demographic Information
Gender/Race/Ethnicity %
Sex/Gender
Female
Male

Other
Black
Multi-Racial
White
Total

SD
.492

5.27

.993

5.02

1.398

41.13
58.90
Ethnicity

Spanish/Latino
None of the Above
Haitian
Unknown

M
1.59

5.25
89.34
0.14
5.23
Race
1.22
29.70
4.00
65.10
100
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Table 2
Means and Standard Deviation for Adult Demographic Information
Marital Status

Percentages

Divorced/Legal Separated
Married/not legally separated
Never Married
Unreported
Widowed
Total

17.14
16.75
63.15
0.93
2.04
100

M
3.62

SD
1.505

Table 3
Means and Standard Deviation for Adult Demographic Information
Education/Employment

Percentages
Education

4th grade and under
5th to 8th grade
9th to 12th grade, no diploma
High School graduate/diploma/ degree
Past/Current college, no diploma
AA, BA, MS degrees
Other Schooling/degree

0.27
7.84
34.40
34.00
12.98
8.64
1.87

Employed
Unemployed
Disabled
Student
Total

Employment
27.76
52.88
7.12
12.24
100

M
8.68

SD
5.673

11.81

5.410
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Table 4
Chi-Square Test: Heroin Use by Secondary Substance

Pearson Chi-Square

Value
25.632a

Likelihood Ratio
Linear-by-Linear Association

26.500
0.274

N of Valid Cases

915

a. 2 cells (14.3%) have expected count less than 5.

df

6

Asymptotic
Significance (2sided)
0.000

6
1

0.000
0.601
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Figure 2: Patient Ethnicity and MAT Treatment
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Figure 3: Race of Patient and MAT Treatment
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Figure 4: Employment Status of Patient and MAT Treatment
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Figure 5: Marital Status of Patient and MAT Treatment
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Figure 6: Education Attained and MAT Treatment

40

OPIOID USE DISORDER: THE UGLY RETURN AND TREATMENT

41

35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%

Figure 7: Primary Substance and MAT Treatment

No MAT
Yes MAT

OPIOID USE DISORDER: THE UGLY RETURN AND TREATMENT

8.00%
7.00%
6.00%

Percentage of Patients

5.00%
4.00%
3.00%
2.00%
1.00%
0.00%

Figure 8: Secondary Substance and MAT Treatment

No MAT
Yes MAT

42

OPIOID USE DISORDER: THE UGLY RETURN AND TREATMENT

3.00%

Percentage of Patients

2.50%

2.00%

1.50%
No MAT
1.00%

0.50%

0.00%

Figure 9: Tertiary Substance and MAT Treatment
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Figure 10: Heroin and Other Opioid Use by Percentage of Patients for Primary Substance
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Figure 11: Heroin and Other Opioid Use by Percentage of Patients for Secondary
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Figure 12: Heroin and Other Opioid Use by Percentage of Patients for Tertiary Substance

OPIOID USE DISORDER: THE UGLY RETURN AND TREATMENT

5000

Hispanic

4500

NonHispanic

4000

Number of Patients

3500
3000
2500
2000
1500
1000
500
0
No Heroin Use

Yes Heroin Use
Heroin Use

Figure 13: Heroin Use and Ethnicity

47

OPIOID USE DISORDER: THE UGLY RETURN AND TREATMENT

3500
No Heroin
Use
Yes Heroin
Use

3000

Number of Patients

2500

2000

1500

1000

500

0
White

Figure 14: Heroin use and Race

Black
Race of Patients

Other

48

OPIOID USE DISORDER: THE UGLY RETURN AND TREATMENT

Gender
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